Abstract

A binding protein for plasminogen activator inhibitor 1 (PAI-1-BP) was isolated from human plasma by a four-step procedure. 1) The 7 S globulin fraction of plasma was isolated by gel filtration on Sephacryl S-300. 2) Human endothelial cell-type plasminogen activator inhibitor (PAI-1), pretreated with 12 M urea, was added to this fraction (22 micrograms of PAI-1/ml of plasma), and a PAI-1 antigen peak with apparent mass 450 kDa (representing 65% of PAI-1 antigen and 85% of PAI activity) was isolated by gel filtration of this mixture. 3) The PAI-1.PAI-1-BP complex was further purified by immunoadsorption on an immobilized murine monoclonal antibody directed against PAI-1 (MA-7D4) and by elution with 4 M KSCN. 4) The complex was then dissociated by addition of excess human tissue-type plasminogen activator (t-PA), and t-PA and PAI-1 antigen (t-PA.PAI-1 complexes and free t-PA and PAI-1) were removed by immunoadsorption on monoclonal antibodies directed against t-PA (MA-62E8) and against PAI-1 (MA-7D4 and MA-12A4). Sodium dodecyl sulfate-gel electrophoresis of the purified material under nonreducing conditions revealed two bands with apparent mass approximately equal to 150 kDa and two bands with mass 74 and 68 kDa. Reduced sodium dodecyl sulfate-gel electrophoresis displayed two main bands with apparent masses of 73 and 64 kDa. The PAI-1-BP reacts with urea-treated, but not with inactive PAI-1. t-PA dissociates the complex between PAI-1 and PAI-1-BP. PAI-1 in complex with PAI-1-BP is 2-3-fold more stable at 37 degrees C than purified PAI-1, suggesting that PAI-1-BP may stabilize PAI-1 in blood. The concentration of PAI-1-BP in plasma determined by titration with PAI-1 is approximately 130 mg/liter. The isolated PAI-1-BP was shown to be identical to S protein (vitronectin) both by cross-reactivity with monospecific rabbit antisera and by NH2-terminal amino acid sequence analysis. The gel filtration behavior, mobility on sodium dodecyl sulfate-gel electrophoresis, and concentration in plasma suggest that PAI-1-BP is a multimer (presumably a dimer) of S protein accounting for approximately 35% of the S protein in plasma.

Highlights

  • Analysis of the interaction of purified PAI-1-BP or S protein with PAI-1showed that: 1)both react with urea-treated

  • The occurrence of a PAI-1 binding protein in human plasmPaAI-1 but not withinactive PAI-1; 2) both react with PAI-1 wasrecently demonstrated

  • We to form a complex with increased mobility on agarose gel have isolated and characterized this binding proteinP,AI-1- electrophoresis; 3) both give rise to theoccurrence of PAI-1

Read more

Summary

Introduction

DeclerckS, Maria De Mol,Marie-Christine AlessiO, Siegfried Baudnerll, Eric-Paul PiiquesY, Klaus T. A binding protein for plasminogen activator inhibi- BP is a multimer (presumably a dimer) of S protein tor 1(PAI-1-BP) wasisolated from human plasma by accounting for approximately 35% of the S protein in a four-step procedure. 2) Human endothelial cell-type plasminogen activator inhibitor (PAI-1), pretreated with 12 M urea, was added tothisfraction(22 pgof PAI-l/ml of Plasminogen activators are serine proteases which convert plasma), and aPAI-1antigen peak with apparemntass plasminogen, the proenzyme of the fibrinolytic system in. 3)The PAI-1 *PAI-1-BPcomplex was further activator inhibitors(PAI).’. Three different types of PA1 have purified by immunoadsorption on an immobilized mu- been identified [2]: the endothelial cell-type PA1 (PAI-1), the rine monoclonal antibody directed againstPAI- 1(MA- placenta-type PA1 (PAI-2) and the urinary-type PA1 450 kDa (representing 65%of PAI-1 antigen and85% blood, to plasmin which in turn digests fibrin [1].The activity of PA1 activity) was isolated by gel filtration of this of the plasminogen activators is controlled by plasminogen mixture. 3)The PAI-1 *PAI-1-BPcomplex was further activator inhibitors(PAI).’ Three different types of PA1 have purified by immunoadsorption on an immobilized mu- been identified [2]: the endothelial cell-type PA1 (PAI-1), the rine monoclonal antibody directed againstPAI- 1(MA- placenta-type PA1 (PAI-2) and the urinary-type PA1

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call